Covidien, a subsidiary of Medtronic, has agreed to pay almost $20 million to settle allegations by the DOJ that the company violated the anti-kickback statute of the False Claims Act when it induced California- and Florida-based health providers to purchase its ClosureFast radiofrequency ablation catheters from 2011 to 2014. This is not the first time Medtronic paid millions to settle allegations, as the company agreed to pay $51 million for introducing an adulterated medical device into interstate commerce in 2018, and agreed to pay $12 million for deceptively marketing one of its devices known as Infuse.
